《新股表现》赛生药业(06600.HK)暗盘高开6.4%报20元
根据辉立交易平台显示,明天挂牌的赛生药业(06600.HK)暗盘高开6.4%报20元暂欠承接,最低见18.8元,现造19元,较上市价18.8元,高1.1%,成交22万股。
赛生药业是一家拥有产品开发和商业化集成平台的生物制药公司,其战略上专注於内地一些最大且发展迅速存在重大未满足医疗需求的治疗领域,主要包括肿瘤及重症感染。 公司也力图在重点治疗领域开发优质上市产品(包括自有产品日达仙)及在研药物组合并对其进行商业化。
赛生是次来港上市共发售近1.16亿股,并已引入包括Shanghai Pharmaceutical Lin-gang Special Area、Daguan International、China Post and Capital Global Asset Management等11名基石投资者,合共认购5,513万股(设6个月禁售期);其中10%公开发售获1,067倍超购,已启动回拨机制占比增至50%,认购一手中签率仅3%;股份以招股范围(17.2-18.8元)上限定价,料集资净额约20.4亿元,主要用於投资内地或其他全球市场潜在药物收购和授权、还债、用作开发和商业化临床阶段候选产品、招聘与扩大销售网络及商业和开发基础设施、为持续临床研究提供资金。上市联席保荐人分别为大摩、中金及瑞信。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.